Pembrolizumab for abnormal cells on the cervix
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests pembrolizumab (an immune treatment) to see if it can treat high-grade abnormal cells of the cervix (CIN 2/3 or carcinoma in situ). You may need biopsies during the study and a planned procedure after about 24 weeks to remove or sample the cervix tissue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are assigned female and age 21 or older.
- You have confirmed CIN grade 2 or 3 or carcinoma in situ (non-invasive) that has not been surgically removed yet.
- You are not pregnant or breastfeeding, and you can follow pregnancy prevention rules during treatment and for at least 120 days after the last dose (if you can become pregnant).
- You can provide stored cervical tissue or do a new biopsy from a lesion that has not had prior radiation.
- You can agree to: (1) a repeat mid-study biopsy after cycle 2 if a spot is available, and (2) a planned procedure after about 24 weeks (LEEP or cold-knife cone), unless your doctor says it’s unsafe.
- You have good baseline health for treatment (ECOG 0–1) and your recent lab tests are within normal limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies pembrolizumab (an immune medicine) for leukoplakia and related abnormal mouth patches with moderate/severe pre-cancer changes. It aims to see whether the treatment can shrink or control the lesions when surgery or radiation isn’t an option.
This Phase 2 trial studies whether pembrolizumab and lenvatinib can improve outcomes in people with advanced cervical cancer that has grown or stopped responding to earlier treatments. It may help by boosting the immune system and slowing cancer growth.
This trial tests whether adding two drugs (pembrolizumab and lenvatinib) to standard chemoradiation and brachytherapy can improve outcomes for people with high-risk locally advanced cervical cancer. It is designed for patients who are fit enough to undergo intensive treatment.
This trial tests a new immunotherapy drug, serplulimab, for people with locally advanced cervical cancer. The goal is to see if it can help shrink or control the cancer before standard treatments.
This trial tests combining an immunotherapy drug (pembrolizumab) with a special type of radiation (carbon-ion radiotherapy) for a specific type of advanced cervical cancer called adenocarcinoma or adenosquamous carcinoma. It aims to see if this combination is safe and effective for patients who have not had prior radiation or chemotherapy for their cervical cancer.
This trial tests a lower dose of pembrolizumab combined with standard chemotherapy as a first treatment for cervical cancer that has spread, come back, or cannot be removed by surgery. The goal is to see if this combination can help shrink tumors and slow the cancer's growth.
Hear when a new Cervical Intraepithelial Neoplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.